A phase I double-blind, randomized, placebo-controlled, single-ascending dose study to evaluate the Safety and Pharmacokinetics of SAR-252067

Trial Profile

A phase I double-blind, randomized, placebo-controlled, single-ascending dose study to evaluate the Safety and Pharmacokinetics of SAR-252067

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs AEVI 002 (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 12 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top